Episurf Medical reaches new milestones in its patient population
Episurf Medical (Nasdaq: EPIS B) today announces that the company has reached new milestones in its patient population as more than 100 Episealer® patients now have had their knee implants for more than 3 years, and more than 200 patients have had the implants for more than 2 years.
A few months ago, the company announced that 500 patients had been treated with the Episealer® knee implant. The company now reports increasing patient populations in the important 2 and 3-year follow-up periods. A significant part of the patients treated, especially among the first patients which were treated with the Episealer® implant, are being followed-up and monitored in clinical studies. Results reported to date show significant improvements on all important measuring points, including pain, symptom and quality of life in addition to low implant revision rates.
“This is all very re-assuring and we are becoming excited about the prospects for this ground-breaking technology. The truth is that, as much as knee pain and related problems are extremely common in the society, it has also been very challenging to treat patients in the stage before they are candidates for a comprehensive knee prosthesis surgery. This is where we come in, and the results make our entrance very interesting.
Three years is a significant time threshold since our revision statistics as well as from other similar devices show that almost all implant revisions occur within three years from surgery. Data suggests that having passed that time, the implant may last for a very long time. Growing patient groups among those who have had the implant for a significant time is definitely an important step”, says Prof. Leif Ryd, Senior Medical Advisor to Episurf Medical.
"This development shall be seen in the perspective of the increasing attention we are receiving. As an example, for the first time, clinical results are to be presented at a podium presentation at a major international knee congress later this fall. All in all, we believe we are taking some significant steps these days" says Pål Ryfors, CEO Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
Tags: